David Ricks runs one of the leading pharmaceutical companies whose experimental coronavirus therapy, bamlanivimab, already received emergency FDA approval. As cases continue to climb across the country and with vaccine approval within reach, Ricks joins Washington Post columnist David Ignatius to discuss the progress and latest developments. Join Washington Post Live on Tuesday, Dec. 15 at 1:30 p.m. ET.

Stream here: wapo.st/davidricks